Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Characterization and Localization of Focal Atrial Tachycardia in Patients With Adult Congenital Heart Disease.
JACC Clin Electrophysiol
January 2025
Cardiac Electrophysiology Section, Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA. Electronic address:
Background: In patients with structurally normal hearts, algorithms using surface electrocardiographic P-wave morphology are helpful to predict focal atrial tachycardia (FAT) location. However, these algorithms have not been formally assessed in patients with adult congenital heart disease (ACHD).
Objectives: This study sought to assess the efficacy of FAT-location prediction algorithms in an adult population of patients with ACHD.
A deep-learning system integrating electrocardiograms and laboratory indicators for diagnosing acute aortic dissection and acute myocardial infarction.
Int J Cardiol
January 2025
Department of Computer Center, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, China.
Background: Acute Stanford Type A aortic dissection (AAD-type A) and acute myocardial infarction (AMI) present with similar symptoms but require distinct treatments. Efficient differentiation is critical due to limited access to radiological equipment in many primary healthcare. This study develops a multimodal deep learning model integrating electrocardiogram (ECG) signals and laboratory indicators to enhance diagnostic accuracy for AAD-type A and AMI.
View Article and Find Full Text PDFSafety and Efficacy of Fingolimod and Ocrelizumab in Pediatric Patients With Multiple Sclerosis.
Pediatr Neurol
January 2025
Division of Pediatric Neurology, Department of Neurology, University of Virginia, Charlottesville, Virginia. Electronic address:
Background: Fingolimod and ocrelizumab are approved treatments for adults with multiple sclerosis (MS); however, only fingolimod is approved by the Food and Drug Administration for the treatment of pediatric MS. Currently, there are limited data for the safety and efficacy of ocrelizumab use in children.
Methods: This retrospective cohort study included patients with relapsing-remitting MS who started either ocrelizumab or fingolimod before age 18 years.
Predicting the Propensity of Atrial Cardiopathy and Paroxysmal Atrial Fibrillation in Patients with Embolic Stroke of Undetermined Source (ESUS).
Arq Bras Cardiol
January 2025
Cardiovascular Medicine Department, Faculty of Medicine, Tanta University, Tanta - Egito.
Background: There is still a significant population of patients with embolic stroke of Undetermined Source (ESUS) whose specific attributable cause of the stroke remains unknown.
Objectives: Our research aimed to assess clinical, electrocardiogram, laboratory, and echocardiographic parameters that may predict the propensity of paroxysmal atrial fibrillation (PAF).
Methods: We enrolled seventy-five ESUS patients who were in sinus rhythm at the time of stroke diagnosis to undergo in-hospital 7-day Holter monitoring, testing for Pro-BNP, and a standard echocardiographic examination.
Which Test is Best for Pain in the Chest?
R I Med J (2013)
February 2025
Professor of Medicine, Clinician Educator, Warren Alpert Medical School, Brown University; Associate Chief, Cardiology, Brown University Health Cardiovascular Institute, Providence, Rhode Island.
Chest pain is one of the most common chief complaints seen in both the emergency department (ED) and primary care settings.1,2 It is estimated that 20-40% of the general population will suffer from chest pain at some point throughout their lives.3 Interestingly although obstructive coronary artery disease (CAD) prevalence has declined, chest pain as a presenting symptom has become increasingly common over the last decade.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!